Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis

Table 2

The summary of the secondary outcomes.

Outcomes	Z test	OR (95% CI)
SBM responder rate
Linaclotide vs. placebo	6.12	2.41 (1.82, 3.20)	<0.001
Low-dose group vs. medium-dose group	1.42	0.75 (0.50, 1.12)	0.156
Responder rate of the global assessment of relief
Linaclotide vs. placebo	5.87	3.45 (2.28, 5.22)	<0.001
Low-dose group vs. medium-dose group	0.49	0.95 (0.77, 1.17)	0.626
Responder rate of abdominal bowel habits improvements
Linaclotide vs. placebo	7.08	3.73 (2.59, 5.36)	<0.001
Low-dose group vs. medium-dose group	1.20	1.29 (0.85, 1.97)	0.230
Responder rate of abdominal symptoms relief
Linaclotide vs. placebo	10.42	2.76 (2.283.34)	<0.001
Low-dose group vs. medium-dose group	0.45	0.91 (0.61, 1.36)	0.65
Outcomes	Z test	RR (95% CI)
Adverse events between the linaclotide group and placebo
Any adverse events	4.88	1.23 (1.13, 1.33)	<0.001
Gastrointestinal disorders	3.31	2.03 (1.34, 3.09)	0.001
Diarrhea	9.12	3.10 (2.43, 3.95)	<0.001
Infections	3.15	1.45 (1.15, 1.83)	0.002

OR, odds ratio; RR, risk ratio; CI, confident interval.